Serotonin Syndrome

Serotonin syndrome, also termed serotonin toxicity, is a clinical toxidrome characterized by the triad of altered mental status, autonomic instability, and neuromuscular abnormalities ^[3]D5. It results from excessive serotonergic agonism in the central and peripheral nervous systems, most commonly precipitated by drug interactions, therapeutic dose combinations, or overdose.

Nomenclature and Spectrum

The condition is referred to interchangeably as serotonin syndrome (SS) or serotonin toxicity, the latter emphasizing that it is a dose-dependent toxic effect rather than an idiosyncratic reaction. The syndrome exists on a continuum: at the mild end, patients may exhibit only tremor, diarrhea, and mild hyperreflexia; at the severe end, life-threatening hyperthermia, muscle rigidity, and multiorgan failure can occur ^[3]D5.

Etiological Context

Serotonin syndrome is predominantly iatrogenic. The highest risk combinations involve monoamine oxidase inhibitors (MAOIs) with other serotonergic agents, though even in the modern era, coprescribing of serotonergic drugs occurs in 18.1% of MAOI-treated patients ^[1]B2b. Common precipitants include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and drugs such as fentanyl , which can unmask the syndrome during procedural sedation ^[5]C4. In oncology populations, potential major drug interactions that could lead to serotonin syndrome are frequent and are associated with a 2.28-fold increase in hospital and emergency department visits (OR 2.28, 95% CI 1.33-3.92) ^[4]B2b.

Clinical Significance

Though no formal classification system exists, clinicians must recognize that serotonin syndrome is a potentially fatal condition that can progress rapidly from mild symptoms to severe toxicity ^[3]D5. Emergency physicians, toxicologists, and any clinician prescribing serotonergic agents must maintain a high index of suspicion, as early recognition is the cornerstone of preventing deterioration. The next section details the underlying mechanisms that drive this dangerous differential.

Pearl: Most cases are iatrogenic, often from drug interactions involving MAOIs, SSRIs, SNRIs, or fentanyl.

The classification and nomenclature outlined above provide the framework for recognizing serotonin syndrome, but the clinician facing an undifferentiated patient with hyperthermia, rigidity, and altered mental status must hold several competing life-threatening mechanisms in parallel. Each arises from a distinct pathophysiology, serotonin excess, dopamine blockade, cholinergic blockade, or volatile anesthetic-induced calcium release, and each demands a different therapeutic response. The following table organizes the key features that separate these entities at the bedside.

Comparison of Hyperthermic-Rigidity Syndromes

When to Suspect Each Alternative

• Neuroleptic malignant syndrome rises in the differential when the patient is on typical or atypical antipsychotics, has lead-pipe rigidity without clonus, and symptoms developed over several days ^[11]D5.
• Anticholinergic toxidrome should be considered when the patient has hot, dry skin, dilated pupils, and decreased bowel sounds, especially after exposure to antihistamines, tricyclic antidepressants, or atropine ^[11]D5.
• Malignant catatonia is suggested by the presence of catatonic signs (posturing, waxy flexibility, mutism) that improve with benzodiazepines, and is often a diagnosis of exclusion ^[22]D5.

Must-Not-Miss Differentials

• Malignant hyperthermia - Suspect in any perioperative patient who develops hyperthermia, rigidity, and metabolic acidosis within minutes to hours after exposure to volatile anesthetics or succinylcholine. Confirm with elevated end-tidal CO₂, mixed venous desaturation, and history of anesthesia. Immediate dantrolene 2.5 mg/kg IV is lifesaving ^[10]D5.
• Baclofen withdrawal - Consider in patients on chronic baclofen who rapidly develop hyperthermia, rigidity, seizures, and autonomic instability after abrupt cessation. Rule out by history and response to baclofen reinstitution ^[10]D5.
• Sympathomimetic toxidrome - Presents with hyperthermia, hypertension , tachycardia, and agitation but typically lacks clonus or rigidity. Urine drug screen for cocaine, amphetamines, or MDMA may be positive ^[10]D5.

When to Reconsider the Diagnosis

• If the patient meets Hunter criteria but has no clear exposure to a serotonergic agent (e.g., on a 5-HT₂A antagonist like olanzapine or ondansetron), reconsider alternative diagnoses such as sepsis, metabolic encephalopathy, or withdrawal ^[8]D5.
• If symptoms progress beyond 24 hours after stopping the offending agent, look for occult pharmacobezoar (e.g., extended-release carbamazepine-venlafaxine overdose) or ongoing absorption ^[16]C4.
• If rigidity is severe and respiratory compromise progresses despite adequate sedation and paralysis, consider that the diagnosis may be NMS or malignant catatonia rather than serotonin syndrome alone ^[8]D5[12]D5.

Pearl: When clonus is absent, neuroleptic malignant syndrome or malignant catatonia is more likely than serotonin syndrome, and the distinction matters because dantrolene is indicated for NMS, not SS, while benzodiazepines and supportive care are the cornerstone for both.

From the synaptic mechanisms that drive serotonin toxicity, the clinical question becomes: how often does this occur, and in whom? The answer is sobering: serotonin syndrome is rare in general populations but strikingly common in specific clinical contexts, and it is almost systematically underdiagnosed.

Incidence and Prevalence

In large US claims databases, annual serotonin syndrome incidence declined from 0.19% to 0.07% (Veterans Health Administration) and 0.17% to 0.09% (commercially insured) over the study period ^[28]B2b. Overall prevalence also decreased ^[28]B2b. These figures likely underestimate true incidence because the condition is frequently missed. In a prospective 6-month ICU study, 7.8% (24/309) of consecutive medical ICU admissions met Hunter criteria for serotonin syndrome, yet none had been diagnosed by the treating physicians ^[29]C4. The mean age was 52.4 years, and 75% were male ^[29]C4.

Among specific drug combinations, incidence is low but not negligible:

• Linezolid monotherapy: 0.005%; linezolid with other serotonergic agents: 0.0134% ^[38]C4
• Tedizolid with concomitant serotonergic agents: 0.4% (2/479) ^[32]B2b
• Fentanyl plus a serotonergic agent: 0.09% (4/4538) met Hunter criteria ^[33]B2b
• Linezolid plus opioids in acutely ill patients: 1.6% had spontaneous clonus, though attribution was confounded ^[30]B2b

Temporal Trends

Incidence appears to be decreasing in claims-based analyses ^[28]B2b, but this may reflect improved coding or shifting prescribing patterns rather than a true decline. The absolute number of cases may rise as serotonergic polypharmacy increases, especially in older adults ^[34]C4.

Risk Factors

The most potent risk is the number of serotonergic drugs: patients prescribed ≥5 non-MAOI serotonergic agents had the highest relative incidence of serotonin syndrome compared to those on a single agent ^[28]B2b. In the ICU, ondansetron (58%), tramadol (38%), and cough syrup containing dextromethorphan or chlorpheniramine (21%) were the most common culprits ^[29]C4. In elderly ambulatory patients, drugs frequently involved in multidrug interactions that amplify serotonin syndrome risk include bupropion, tramadol, trazodone, cyclobenzaprine, fluoxetine , ondansetron, and quetiapine ^[36]C4.

Special Populations

• ICU patients: Prevalence is high (7.8%) and diagnosis is routinely missed ^[29]C4. Overlapping features with sepsis, encephalopathy, and withdrawal syndromes contribute to underrecognition ^[42]D5.
• Elderly with polypharmacy: 2.4% of patients aged ≥65 years on ≥5 medications have a high or moderate risk for serotonin syndrome based on their medication list ^[34]C4.
• Pediatric patients: Among 141,363 children and young adults dispensed behavioral/mental health medications, 250 filled contraindicated pairs that increase serotonin syndrome risk ^[35]C4.
• Post-anesthesia: Delayed emergence after anesthesia may be due to unrecognized serotonin syndrome, especially in patients on serotonergic agents who receive fentanyl ^[43]D5.

Pearl: Serotonin syndrome is not rare in the ICU, 7.8% of medical ICU admissions meet Hunter criteria, yet it is almost never diagnosed by the treating team ^[29]C4. A high index of suspicion, especially in patients on ondansetron, tramadol, or multiple serotonergic agents, is essential to avoid missing this treatable condition.

The clinical presentation of serotonin syndrome mirrors its pathophysiology: a spectrum of toxicity that progresses from mild serotonergic side effects to life-threatening hyperthermia and rigidity ^[8]D5. Onset is rapid, symptoms become apparent within one hour in about 30% of patients and within six hours in 60% ^[8]D5. The classic triad of altered mental status, autonomic instability, and neuromuscular excitation anchors recognition, but the relative prominence of each domain varies with severity ^[8]D5.

Presenting Symptoms

Mild toxicity often manifests as anxiety, restlessness, mild tachycardia, diaphoresis, and gastrointestinal upset. As serotonin concentrations rise, patients develop confusion, agitation, hyperthermia, mydriasis, and neuromuscular hyperactivity. In severe cases, temperature exceeds 40°C, opisthotonus appears, and truncal rigidity progresses to respiratory compromise ^[8]D5. The patient may report a sense of impending doom or visual hallucinations ^[19]C4.

Neurological Examination Findings

Neuromuscular signs are the most specific and diagnostically useful. Clonus, spontaneous, inducible, or ocular, is the hallmark ^[8]D5. Inducible clonus is elicited by rapid dorsiflexion of the ankle; ocular clonus is seen as slow, lateral gaze-evoked nystagmus. Hyperreflexia, myoclonus, and tremor (especially in the lower extremities) are common. Rigidity, particularly in the lower limbs and trunk, signals severe toxicity and may impair chest wall compliance ^[8]D5. Autonomic findings include tachycardia, hypertension or hypotension, diaphoresis, flushing, and mydriasis. Mental status ranges from agitated delirium to coma.

Phenotypic Variants

Red Flags

• Temperature >39°C that rises rapidly over hours ^[8]D5.
• Sustained spontaneous clonus or opisthotonus.
• Truncal rigidity with FVC <15 mL/kg, consider imminent respiratory failure and need for intubation ^[8]D5.
• Altered consciousness with autonomic instability (tachyarrhythmias, labile blood pressure).
• Failure to respond to initial benzodiazepines.

Atypical Presentations

Serotonin syndrome can be mistaken for other conditions when the classic triad is incomplete. In elderly patients, delirium may be the sole presenting feature, especially when serotonergic drugs are used at therapeutic doses ^[58]C4. In the perioperative setting, intraoperative rigidity, hyperthermia, and arrhythmias mimic malignant hyperthermia ^[57]C4. Patients with Parkinson's disease may have overlapping tremor and rigidity, delaying diagnosis ^[50]C4. A subacute variant without autonomic instability has been described in patients on stable antidepressant therapy, presenting with unexplained cognitive decline, motor slowing, or psychosis ^[48]C4. Clinicians should maintain a low threshold for considering serotonin syndrome in any patient on serotonergic agents who develops unexplained neurological or psychiatric symptoms.

Pearl: The most specific sign of serotonin syndrome is clonus, spontaneous, inducible, or ocular. When present in a patient on serotonergic drugs, it should prompt immediate evaluation and cessation of offending agents, even if autonomic instability is absent ^[8]D5.

From the clinical features described above, the diagnostic challenge becomes apparent: serotonin syndrome shares overlapping manifestations with several life-threatening conditions. The emergency clinician must systematically exclude each can't-miss alternative before converging on the diagnosis.

Worst-First Differential

Gold-Standard Diagnostic Criteria

The Hunter Serotonin Toxicity Criteria are the preferred diagnostic instrument, as they demonstrate higher specificity than the Sternbach criteria ^[14]C4. "The Hunter Serotonin Toxicity Criteria are considered the most accurate and clinically useful diagnostic tool, particularly in moderate to severe cases" ^[14]C4. A patient meets the Hunter criteria if, in the setting of serotonergic drug exposure, they have one or more of the following:

• Spontaneous clonus
• Inducible clonus plus agitation or diaphoresis
• Ocular clonus plus agitation or diaphoresis
• Tremor plus hyperreflexia
• Hypertonia plus temperature >38°C plus ocular or inducible clonus

In a systematic review of 764 cases, 85.6% met Sternbach criteria and 65.0% met Hunter criteria, reflecting the latter's greater specificity ^[60]C4.

Laboratory Studies

No specific biomarker confirms serotonin syndrome. Order the following to exclude alternative diagnoses and assess severity:

• Creatine kinase: elevated in moderate-severe cases ( rhabdomyolysis ); levels >1000 U/L suggest NMS or severe SS
• Complete blood count : leukocytosis may occur but is nonspecific
• Serum electrolytes, BUN, creatinine: assess for hyponatremia (SIADH can co-occur ^[18]C4) and renal function
• Liver function tests: may be elevated in severe SS with hepatic injury ^[17]C4
• Coagulation profile: DIC-like state can occur in fatal cases ^[17]C4
• Arterial blood gas: metabolic acidosis from hyperthermia and muscle activity
• Thyroid function tests: to rule out thyroid storm
• Blood cultures, urinalysis, CSF analysis: when infection is suspected

Imaging

Non-contrast CT head is indicated to exclude intracranial hemorrhage, stroke, or mass lesions in patients with altered mental status. No imaging finding is diagnostic of serotonin syndrome.

Diagnostic Algorithm

Stepwise approach: Start with the Hunter criteria at the bedside. If positive, the diagnosis is established. If negative, systematically evaluate each alternative using the rule-out instruments above. Once serotonin syndrome is diagnosed, assess severity (see next section) and immediately discontinue all serotonergic agents. Symptoms typically appear within 30 minutes to 7 days of drug exposure ^[25]B3b; a careful medication history covering this window is essential.

First-Line Treatment at Diagnosis

• Immediate discontinuation of all serotonergic drugs (including antidepressants, opioids, linezolid , triptans, St. John's wort, etc.)
• Supportive care: IV crystalloids, external cooling for hyperthermia, benzodiazepines (e.g., lorazepam 1-2 mg IV) for agitation, tremor, and myoclonus
• For moderate-severe cases: the serotonin antagonist cyproheptadine (initial dose 12 mg orally or via NG tube, then 2 mg every 2 hours up to 32 mg/day) ^[14]C4
• For severe hyperthermia (>41°C) or rigidity: non-depolarizing neuromuscular blockade (e.g., vecuronium) with intubation and mechanical ventilation ^[14]C4

Pearl: The Hunter criteria can be applied in seconds at the bedside, spontaneous clonus plus a history of serotonergic drug exposure is enough to make the diagnosis and start treatment without waiting for lab results.

Once the diagnosis is established, and the worst-first differential has been ruled out, the next step is to assign an acuity tier that drives the triage disposition, the monitoring intensity, and the urgency of intervention. Serotonin toxicity exists on a spectrum, and severity determines whether the patient can be observed at home, managed on a medical ward, or requires immediate ICU-level care ^[8]D5.

Severity Spectrum

Serotonin toxicity is categorized into three tiers based on clinical features, not on the ingested dose (which correlates poorly with severity) ^[8]D5:

Adapted from the spectrum described in Chiew & Isbister ^[8]D5.

Severe toxicity is distinguished by hyperthermia >40°C with increasing rigidity, particularly truncal rigidity that eventually impairs respiratory function ^[8]D5. This pattern occurs almost exclusively in patients who have ingested a combination of a monoamine oxidase inhibitor (MAOI) and another serotonergic agent (e.g., SSRI, SNRI), a combination that produces serotonin toxicity in nearly half of cases and is responsible for virtually all life-threatening presentations ^[8]D5. The median time to fatal serotonin syndrome is 1 day ^[54]D5.

Triage Decision-Making

Triage must account for the specific agent, the intent, and the severity of symptoms. The following evidence-based thresholds guide disposition:

• Intentional overdose or suicidal ideation: Refer to an emergency department regardless of dose ^[72]A1c.
• Any symptom beyond mild effects: Mild effects are defined as occasional vomiting, somnolence (lightly sedated and arousable), mydriasis, or diaphoresis. Patients with more than these symptoms (e.g., spontaneous clonus, hyperreflexia, agitation, hyperthermia) require ED evaluation ^{[72]A1c[71]A1c}.
• Asymptomatic SSRI overdose: For ingestions of immediate-release SSRIs up to five times the initial adult therapeutic dose (e.g., citalopram 100 mg, escitalopram 50 mg, fluoxetine 100 mg, sertraline 250 mg), home observation with poison-center follow-up is appropriate ^[72]A1c.
• Dextromethorphan overdose: Ingestions >7.5 mg/kg warrant ED referral; ingestions of 5-7.5 mg/kg require poison-center follow-up every 2 hours for 4 hours ^[71]A1c.
• Known MAOI co-ingestion: This combination carries a high risk of severe toxicity; even if the patient appears asymptomatic, they should be referred to an ED capable of ICU-level care ^[8]D5[71]A1c.

Risk Factors for Severe Toxicity

• Drug combination: MAOI + SSRI/SNRI is the predominant risk factor. Co-ingestion of moclobemide with SSRIs produces serotonin toxicity in approximately half of overdoses ^[8]D5.
• Rapid onset: Symptoms become apparent within 1 hour in about 30% of patients, and within 6 hours in 60% ^[8]D5.
• Older age: Advanced age is a risk factor for fatality in drug-induced QT prolongation, though not independently associated with serotonin syndrome fatality ^[54]D5.
• Genetic factors: Polymorphisms in the SERT gene, 5-HT2 receptors, or CYP pathways may predispose some individuals to toxicity at lower doses ^[8]D5.

Diagnostic Criteria in Risk Stratification

The Hunter Serotonin Toxicity Criteria, most commonly used, were derived from a cohort of single SSRI overdose patients and are best applied to moderate-to-high-risk presentations (e.g., overdose, drug interaction). In low-risk patients (those on stable therapeutic doses), the criteria have poor specificity; alternative diagnoses (e.g., sepsis, metabolic encephalopathy) are often responsible for tachycardia, hyperreflexia, and hyperthermia ^[8]D5. The modified criteria proposed by Chiew et al. require a definitive serotonergic agent (not a 5-HT antagonist like ondansetron) and exclusion of other aetiologies ^[8]D5.

Pearl: The single most important predictor of severe outcome is a rapidly rising temperature >40°C with truncal rigidity, this demands immediate ICU-level care with paralysis and cooling, regardless of the diagnostic label. Do not delay treatment to confirm the diagnosis ^[8]D5.

Once the patient is identified as high-risk, resuscitation begins immediately, before the diagnosis is confirmed. The foundation of acute management is the ABCDE approach, executed in parallel: stop all serotonergic agents, secure the airway if needed, treat hyperthermia, and control agitation and autonomic instability with benzodiazepines ^[10]D5[81]D5. The goal is to prevent progression to fulminant multi-organ failure while the offending drugs are cleared.

Airway and Breathing

Depressed consciousness, severe rigidity, or seizures may compromise the airway. Early intubation is indicated for patients with a Glasgow Coma Scale < 8, refractory hypoxemia, or inability to protect the airway from excessive secretions or vomiting ^[80]C4[5]C4. Once intubated, maintain sedation with benzodiazepines (e.g., midazolam) to control agitation and muscle rigidity; propofol is an alternative but carries a risk of hypotension. Avoid depolarizing neuromuscular blockers such as succinylcholine because rhabdomyolysis can cause acute hyperkalemia and cardiac arrest, use a non-depolarizing agent like rocuronium if paralysis is required ^[10]D5.

Circulation and Hemodynamics

Autonomic instability can manifest as tachycardia, hypertension , or hypotension. Fluid resuscitation with isotonic crystalloids is the first step for hypotension, and it also helps prevent acute kidney injury from rhabdomyolysis ^[81]D5. If vasopressors are needed, norepinephrine is preferred over dopamine because dopamine may exacerbate tachyarrhythmias in the setting of excess serotonin activity ^[10]D5. Monitor for electrocardiographic abnormalities: venlafaxine overdose can cause QRS widening and left ventricular dysfunction with ejection fractions as low as 15-18% ^[80]C4; obtain a 12-lead ECG and echocardiogram early if cardiotoxicity is suspected.

Temperature Control

Hyperthermia is a core driver of morbidity. Immediate cooling with evaporative techniques, ice packs, and cold intravenous fluids is indicated for core temperature > 39 °C ^[10]D5. Antipyretic agents such as acetaminophen are ineffective because hyperthermia in serotonin syndrome results from excessive muscle activity and central thermoregulatory dysregulation, not from a reset hypothalamic set point. Benzodiazepines are the first-line pharmacotherapy to reduce muscle hyperactivity and heat generation; they simultaneously calm agitation and autonomic instability ^[81]D5.

Drug Withdrawal and Targeted Pharmacotherapy

The single most important intervention is discontinuation of all serotonergic agents, SSRIs, SNRIs, MAOIs, linezolid , methylene blue, fentanyl , and any other drugs that enhance serotonin activity ^[10]D5. For mild to moderate cases, benzodiazepines alone may suffice. For severe or refractory cases (e.g., with persistent hyperthermia, rigidity, or autonomic instability despite benzodiazepines), serotonin antagonists such as cyproheptadine may be considered, though evidence is limited to case reports ^[10]D5. A multidisciplinary approach involving critical care, toxicology, and pharmacy is essential ^[10]D5.

Pearl: The most time-critical action is to stop all serotonergic drugs and start benzodiazepines, this single step can prevent progression from mild to life-threatening disease. Do not wait for laboratory confirmation; begin resuscitation based on clinical suspicion.

Once the patient with severe serotonin toxicity is identified by a rapidly rising temperature >39°C, truncal rigidity, and altered mental status, the next critical step is securing the airway, providing deep sedation, and initiating neuromuscular blockade, not as a last resort, but as a life-saving intervention ^[8]D5. The goal is to abolish muscle activity, halt hyperthermia, and prevent the cascade of rhabdomyolysis , multiorgan failure, and death.

Procedural Sedation: Agents and Pitfalls

Benzodiazepines remain first-line for agitation and mild-to-moderate toxicity, but in severe cases they are insufficient. Propofol (50 mg/h continuous infusion, as used in the reported adolescent case) provides reliable sedation and reduces cerebral metabolic demand, but does not itself paralyze ^[19]C4. Dexmedetomidine, an α-2 receptor agonist, has been used successfully in three adolescents with severe serotonin syndrome refractory to midazolam and propofol, stabilizing autonomic instability and facilitating extubation ^[90]C4. A 22-month-old with vilazodone overdose also improved without intubation after dexmedetomidine ^[91]C4. However, dexmedetomidine is not a substitute for paralysis when rigidity is severe.

Caution with fentanyl : Although fentanyl is commonly used for analgesia during procedural sedation, it can precipitate or worsen serotonin syndrome in patients taking serotonergic drugs ^[5]C4. In mechanically ventilated patients, concurrent fentanyl and linezolid (a weak MAOI) is associated with increased in-hospital mortality (HR 1.56, 95% CI 1.0-2.43) ^[84]B2b. Avoid fentanyl in the setting of serotonin toxicity; use propofol or dexmedetomidine instead.

Definitive Airway [[Management]] and Neuromuscular Blockade

Indications for endotracheal intubation in serotonin syndrome:

• Temperature >39°C despite sedation and external cooling
• Truncal rigidity impairing ventilation (tachypnea, hypoxemia, hypercapnia)
• Refractory seizures or status epilepticus
• Coma ( GCS ≤8) or rapidly declining mental status

Perform rapid sequence intubation (RSI) with a plan for post-intubation paralysis. Rocuronium (1.2 mg/kg IV bolus, then 5 mg/h continuous infusion) is the agent of choice because it provides rapid onset, reliable paralysis, and avoids the risk of hyperkalemia associated with succinylcholine in the setting of rhabdomyolysis and elevated CK ^[19]C4. Although the published evidence for succinylcholine’s danger in this context is extrapolated from rhabdomyolysis and hyperkalemia literature, the safest approach is to use a non-depolarizing agent. Neuromuscular blockade must be continued until the patient is fully cooled and rigidity resolves, typically for 24-48 hours ^[8]D5.

Active Cooling and Temperature Control

Once the airway is protected and paralysis initiated, active cooling is the most time-critical intervention. Uncontrolled hyperthermia (>40°C) drives rhabdomyolysis, disseminated intravascular coagulation, and multiorgan failure ^[8]D5. Cooling methods:

• Ice-water immersion or ice packs to groin, axillae, and neck
• Cold intravenous saline (4°C, 1 L bolus) if tolerated without fluid overload
• Cooling blankets or intravascular cooling catheters in the ICU
• Avoid antipyretics (acetaminophen, NSAIDs), they are ineffective against toxin-induced hyperthermia

What NOT to do: Do not use dantrolene routinely, animal studies show it does not prevent death in severe serotonin syndrome, and it is more appropriate for malignant hyperthermia ^[8]D5. Do not use chlorpromazine or cyproheptadine as primary therapy for severe hyperthermia; their 5-HT2A blockade is inconsistent and they are not proven to improve outcomes over aggressive supportive care ^[8]D5.

Summary of Sedation and Paralysis Options

Pearl: In severe serotonin toxicity with hyperthermia >39°C and rigidity, the priority is immediate intubation, paralysis, and active cooling; avoid fentanyl and succinylcholine, and do not rely on serotonin antagonists, aggressive supportive care saves lives, not pharmacologic antidotes ^[8]D5[19]C4.

Once the airway is secured and cardiovascular instability is addressed, the ED clinician’s focus shifts to definitive therapy and timely disposition. The core principle, early recognition and treatment are crucial for optimum outcome ^[93]D5, drives every subsequent decision. The steps below outline an ED-centered protocol that stops ongoing serotonin excess, provides symptom-directed pharmacotherapy, and structures the handoff to the admitting service.

Step 1: Immediate Discontinuation of Serotonergic Agents

All drugs that increase serotonin activity must be stopped immediately. This includes SSRIs, SNRIs, MAOIs, linezolid , fentanyl , tramadol, triptans, and over-the-counter agents such as dextromethorphan. The combination of fentanyl and linezolid is particularly concerning: a retrospective cohort study of mechanically ventilated patients found that simultaneous use was associated with significantly higher in-hospital mortality (37.2% vs 22.9%; HR 1.56, 95% CI 1.0-2.43; NNH = 7) ^[84]B2b. Avoid fentanyl for procedural sedation in patients on serotonergic drugs, as it can precipitate serotonin syndrome ^[5]C4.

Step 2: Supportive Care and Symptom Control

Mild cases may require only observation and discontinuation of the offending agent. Moderate to severe cases mandate aggressive supportive care:

• Benzodiazepines are first-line for agitation, myoclonus, and hypertonia. Doses are titrated to effect; no specific dose is reported in the reviewed evidence, but intravenous diazepam 5-10 mg or lorazepam 2-4 mg are commonly used. Repeat as needed to control neuromuscular hyperactivity.
• Mechanical ventilation may be required for severe hyperthermia, refractory seizures, or respiratory failure ^[5]C4.
• Cardiovascular support: Venlafaxine overdose can cause acute left ventricular failure (ejection fraction as low as 15-18%) and cardiogenic shock ^[80]C4. In such cases, aggressive fluid resuscitation (with caution for pulmonary edema), vasopressors, and early involvement of critical care are indicated. Three of four patients in one case series died from refractory hypoxemia, malignant arrhythmias, or cardiogenic shock ^[80]C4.

Step 3: Consideration of Serotonin Antagonists and Advanced Therapies

For moderate to severe serotonin syndrome, consider cyproheptadine (a serotonin 5-HT2A antagonist) as an adjunct. Dosing is not reported in the reviewed abstracts; refer to the drug label. Chlorpromazine (12.5-25 mg IM) has been used for acute agitation but carries a risk of hypotension. No comparative trial data are available from the current evidence base.

In severe venlafaxine (or other SNRI) overdose with cardiovascular collapse, hemadsorption with CytoSorb® may be considered. A case report documented venlafaxine/desmethylvenlafaxine serum levels declining from 53.52 µmol/L to 9.6 µmol/L after 12 hours of hemadsorption, with intact neurological survival after ECLS ^[94]C4. This intervention is not standard of care; it should be reserved for the highest-risk patients and used in consultation with a medical toxicologist and extracorporeal life support team.

Step 4: Time-to-Intervention Targets

No published time-to-treatment thresholds exist for serotonin syndrome, but the evidence underscores that delay in recognition and management increases mortality ^[93]D5. In the venlafaxine case series, patients who died had delayed escalation to advanced therapies ^[80]C4. Goal: initiate supportive care and benzodiazepines within 30 minutes of diagnosis; arrange ICU transfer and toxicology consult within 60 minutes if severe features are present.

Step 5: Structured Handoff to the Admitting Service

A clear handoff ensures continuity of care. Use the following checklist:

• Inciting drugs (list all serotonergic agents, doses, timing of last dose)
• Severity classification (mild/moderate/severe, per section 6)
• Interventions already performed (benzodiazepine doses, IV fluids, airway management, any antidote)
• Ongoing monitoring needs (vital signs, BUN, creatine kinase, continuous ECG for QRS widening, echocardiography if concern for cardiomyopathy)
• Consultations (medical toxicology, critical care, cardiology if cardiotoxic agent)

Management Pathway

Figure 1: ED management algorithm for serotonin syndrome. Adapted from clinical experience and case series ^{[5]C4[80]C4[94]C4}.

Controversies and Guideline Disagreement

Pearl: In severe serotonin syndrome, the time from recognition to ICU admission, benzodiazepine administration, and consultation with toxicology determines outcome, aggressive supportive care and avoidance of serotonergic drugs (especially fentanyl in at-risk patients) are the cornerstones of ED therapy ^{[5]C4[80]C4[93]D5}.

The definitive ED therapy of cyproheptadine and benzodiazepines rests on a foundation of clinical observation and evolving diagnostic frameworks that have shaped the current standard of care over the past four decades.

Early Recognition and the Serotonin Syndrome Concept

The first descriptions of serotonin syndrome emerged from case reports of patients receiving combinations of monoamine oxidase inhibitors (MAOIs) and serotonergic agents. A landmark 1994 report described a 48‑year‑old man who developed confusion, agitation, diaphoresis, and muscle rigidity after starting fluoxetine only two weeks after discontinuing tranylcypromine , illustrating the classic drug‑drug interaction that remains a core mechanism ^[107]C4. Early case series also documented serotonin toxicity with newer antidepressants, including nefazodone and paroxetine ^[108]C4 and with accidental sertraline ingestion in a child ^[109]C4. These reports established that the syndrome could result from therapeutic doses, drug interactions, or overdose, and that the hallmark triad of altered mental status, autonomic instability, and neuromuscular hyperactivity was consistent across diverse serotonergic agents.

Evolution of Diagnostic Criteria

Diagnostic frameworks evolved to improve clinical recognition. The Sternbach criteria, published in 1991, were the first widely used set, but they lacked specificity. The Hunter Serotonin Toxicity Criteria, developed in 2003 from a large prospective validation study, became the preferred clinical tool because they are more sensitive and less likely to yield false positives ^[95]A1b. However, a 2020 clinical review found that the Hunter criteria may miss more cases than the Sternbach or Radomski criteria, cautioning against over‑reliance on any single set ^[99]D5. The same review challenged several assumptions: hyperthermia is not universal, onset is not always rapid, and severe cases do not exclusively involve MAOIs ^[99]D5. These refinements underscore that diagnosis remains a clinical judgment based on the history of serotonergic drug exposure and the presence of characteristic neuromuscular findings.

From Experimental Therapies to Supportive Care

Early management included nonspecific interventions such as dantrolene , which was used in a 1997 case of serotonin syndrome associated with nefazodone and paroxetine ^[108]C4. Dantrolene’s role was subsequently abandoned because it does not directly antagonize serotonin receptors and there is no evidence of benefit over supportive care. Instead, the cornerstone of treatment became prompt discontinuation of the offending agents. A systematic review of linezolid ‑associated serotonin toxicity found that discontinuation alone led to symptom resolution in 75% of cases within 24-48 hours ^[38]C4. For moderate‑to‑severe cases, the 5‑HT2A antagonist cyproheptadine (administered via a nasogastric tube at an initial dose of 12 mg followed by 2 mg every 2 hours if needed) and benzodiazepines for agitation and rigidity became the recommended pharmacotherapy, supported by observational data ^[105]D5.

Safety of Newer Agents and the Role of Monoamine Oxidase Inhibition

The recognition that MAO‑B inhibition could contribute to serotonin toxicity led to scrutiny of newer drugs. Ozanimod , a sphingosine 1‑phosphate receptor modulator, is metabolized to weak MAO‑B inhibitors. A post‑hoc analysis of pooled phase 2/3 trials in ulcerative colitis and relapsing multiple sclerosis found no cases of serotonin syndrome among patients co‑administered ozanimod with SSRIs or SNRIs, and no increase in treatment‑emergent adverse events potentially related to serotonin accumulation ^[96]A1b. Similarly, etrasimod , which lacks the molecular structure to inhibit MAO, showed a low incidence of adverse events potentially associated with serotonin syndrome when co‑administered with opioids or antidepressants (≤8.6%) in the ELEVATE UC trials ^[95]A1b. These findings support a low risk of clinically relevant drug‑drug interactions. In contrast, the 5‑HT1F agonist lasmiditan , used for migraine, was associated with a 0.1% incidence of serotonin syndrome across 4 attacks in the CENTURION trial, although events were not serious ^[103]A1b.

Controversies and Guideline Disagreement

Pearl: When discontinuing the offending agent, 75% of patients with serotonin toxicity will improve within 24-48 hours; if symptoms do not begin to resolve by then, reconsider the diagnosis or search for ongoing serotonergic exposure ^[38]C4.

The history of treatment has evolved from supportive care to targeted serotonin antagonism, but the pivotal decision in the emergency department remains whether the patient can be safely discharged, observed, or requires intensive care. Serotonin syndrome is a high-stakes event: among FAERS cases, 32.89% required hospitalization, 15.11% were classified as life-threatening, and 4.85% resulted in death ^[25]B3b. The disposition decision hinges on the severity of presentation, the mechanism of drug exposure (intentional overdose versus regular prescription), and the patient's medical comorbidities.

Disposition Decision Framework

The most important single determinant is whether the case involves a suicide attempt. Patients with serotonin syndrome following intentional overdose were admitted to the ICU in 79.4% of cases and had a mortality of 18.0%, compared to 35.6% ICU admission and 5.1% mortality among those with regular prescription - a difference that is highly significant (p < 0.001) ^[60]C4. Never discharge a patient with a suicide attempt without a psychiatry consultation ^[60]C4. For regular prescription cases, about 92.9% involve drug combinations (≥2 agents), and monotherapy cases are milder, often occurring after initiation of a new antidepressant in younger patients ^[60]C4.

Criteria for Safe Discharge

A patient can be considered for discharge only when all of the following are met:

• Hunter criteria are not fully met (e.g., only tremor without hyperreflexia or clonus) ^[14]C4.
• No fever (temperature < 38.0°C) and no autonomic instability (heart rate < 100, blood pressure within normal range).
• No rhabdomyolysis, no acute kidney injury, no metabolic acidosis.
• The patient is alert, oriented, and able to communicate.
• The drug exposure was not a suicide attempt (regular prescription only) ^[60]C4.
• A reliable caregiver is available to monitor for 24 hours.
• The patient can return to the ED within 12 hours if symptoms worsen.

Observation Pathway

For patients with moderate symptoms who do not meet discharge criteria and do not require ICU care, observation for 12-24 hours is appropriate. Symptoms typically emerge within 30 minutes to 7 days of the inciting drug exposure, but most cases become apparent within hours ^[25]B3b. After discontinuation of serotonergic agents, 70% of patients experience gradual symptom resolution within 24-36 hours ^[14]C4. The observation period should include:

• Serial vital signs every 2 hours.
• Neurological checks (tremor, clonus, hyperreflexia) every 4 hours.
• Serum creatine kinase and basic metabolic panel at baseline and at 12 hours.
• Continuous cardiac monitoring if any arrhythmia risk (e.g., QTc prolongation from concomitant drugs) ^[66]B3b.

If symptoms do not improve after 24 hours, reassess for alternative diagnoses (e.g., neuroleptic malignant syndrome, catatonia ) ^{[42]D5 [62]C4} and consider drug rebound due to pharmacobezoar formation, especially with extended-release formulations ^[16]C4.

Intensive Care Unit Transfer Criteria

Transfer to ICU is indicated for any of the following:

• Hyperthermia > 41°C (requires aggressive cooling and neuromuscular blockade) ^[14]C4.
• Severe hypertonicity or rigidity leading to respiratory compromise.
• Rhabdomyolysis with creatine kinase > 5000 U/L or acute kidney injury.
• Altered mental status (delirium, coma) or seizures.
• Any intentional overdose, regardless of current symptoms, because of the risk of delayed absorption or rebound ^{[60]C4 [16]C4}.
• Refractory hypotension or cardiac arrhythmias.

ICU management includes sedation with benzodiazepines (e.g., diazepam 10-20 mg IV), physical cooling, and, if needed, non-depolarizing neuromuscular blocking agents (e.g., vecuronium) ^[14]C4. Cyproheptadine, the most commonly used serotonin antagonist, can be given enterally: initial dose 12 mg, then 2 mg every 2 hours if symptoms persist, maximum 32 mg in 24 hours ^[14]C4.

Return Precautions

All patients discharged from the ED or observation unit must receive explicit verbal and written instructions:

• Return immediately if any of the following develop: fever, confusion, muscle stiffness, rapid heart rate, or difficulty breathing.
• Avoid all serotonergic medications (including over-the-counter cough syrups, tramadol, and linezolid ) until cleared by a physician.
• For patients on antidepressants, the responsible psychiatrist should be notified about the serotonin syndrome episode to guide future medication choices.
• If a new drug was the trigger (e.g., linezolid, tramadol), the prescriber should be informed about the interaction ^{[65]C4 [61]B3b}.

Time-to-Intervention Targets

Time from symptom onset to treatment correlates with outcome. The following targets are based on available evidence:

• Recognition: Within 30-60 minutes of ED presentation. Clinicians should maintain a low threshold for applying the Hunter criteria ^[14]C4.
• Drug discontinuation: Immediately upon suspicion. The median time to symptom improvement after drug withdrawal is 8 hours, with most patients improved within 24-36 hours ^[14]C4.
• ICU transfer: Within 1 hour for patients meeting life-threatening criteria.
• Psychiatry consultation: Before discharge for any intentional overdose ^[60]C4.

Pearl: The patient who can be discharged safely is the one with mild symptoms, a regular prescription (not intentional overdose), no fever, and a reliable caregiver who can observe for 24 hours - but even then, hospitalization rates for serotonin syndrome exceed 30% ^[25]B3b, so a low threshold for observation is warranted.

Controversies and Guideline Disagreement

Even after the patient is stabilized and transferred to the ICU, the threat of secondary complications and diagnostic pitfalls persists. The majority of fatalities occur within 24 hours of symptom onset ^[114]C4, and many are preventable with early recognition.

Diagnostic Pitfalls and Cognitive Errors

• Overreliance on diagnostic criteria without drug plausibility: 22% of reported fatal cases were unlikely to be true serotonin toxicity, and 76% had insufficient data to meet Hunter criteria, reflecting overdiagnosis when criteria are applied mechanistically ^[112]D5.
• Knowledge gaps: Only 30.2% of clinicians achieved high knowledge scores on serotonin syndrome, and only 34.5% correctly identified the Hunter criteria ^[65]C4.
• Cognitive biases: Anchoring, premature closure, and availability bias drive misdiagnosis, especially when alternative syndromes (neuropsychiatric lupus, sepsis, anticholinergic toxidrome) are present ^[6]C4[111]C4. The case of a patient with MSSA sepsis initially treated for serotonin syndrome illustrates how sequential biases cascade into harm ^[6]C4.
• Delayed recognition of pharmacobezoar: Extended-release formulations can cause rebound toxicity after initial clearance; one case required hemicolectomy for bowel ischemia ^[16]C4.
• Overlap syndromes: Dyskinesia-hyperpyrexia syndrome in Parkinson's disease and neuroleptic malignant syndrome are frequently confused with serotonin syndrome ^{[121]C4[98]C4}.

Respiratory Monitoring

Respiratory failure is a common complication in severe cases, with mean pO2 of 74.93 mmHg reported in patients receiving dantrolene for hypermetabolic syndromes ^[113]C4. No specific FVC thresholds have been validated for serotonin syndrome, but intubation should be considered for patients with refractory hypoxemia, inability to protect the airway from seizures or severe hyperthermia, or progressive hypercapnia.

Autonomic Complications

Autonomic instability is a hallmark of severe serotonin toxicity. Tachycardia, hypertension , and hypotension can occur; arrhythmias including ventricular tachycardia have been reported ^[16]C4. Ileus and urinary retention may result from anticholinergic contributions or sedation. Active management includes fluid resuscitation, vasopressors as needed, and bowel/bladder protocols.

DVT/PE Prophylaxis

Given immobilization from seizures, sedation, or paralysis, standard prophylactic anticoagulation should be initiated. While no specific agent is validated in serotonin syndrome, we recommend enoxaparin 40 mg subcutaneously daily or unfractionated heparin 5000 units twice daily, following institutional protocols.

Pain Management

Pain is common in this population, but serotonergic analgesics (tramadol, meperidine) are contraindicated. Non-opioid options (acetaminophen, NSAIDs) and non-serotonergic opioids ( morphine , hydromorphone ) are preferred ^[39]D5[59]C4.

Rehabilitation

Early mobilization and physical therapy should be initiated as soon as the patient is hemodynamically stable and neuromuscular symptoms have resolved to prevent deconditioning and contractures.

Hospital-Acquired Complications

Standard ICU bundles, oral care, head -of-bed elevation, early mobilization, and catheter removal, should be applied to prevent ventilator-associated pneumonia , pressure injuries, and catheter-associated urinary tract infections.

Pearl: In any patient with suspected serotonin syndrome, the most dangerous pitfall is not the syndrome itself but the failure to consider an alternative diagnosis, especially when the drug history does not plausibly support serotonin toxicity; 22% of reported fatalities were not actually serotonin syndrome ^[112]D5.

Despite the potential for life-threatening complications such as rhabdomyolysis , seizures, and hyperthermia, the prognosis of serotonin syndrome is generally favorable with prompt recognition and appropriate management . The natural history depends on the severity of serotonin excess, the pharmacokinetics of the offending agents, and the timeliness of intervention.

Natural History and Recovery Timeline

Symptoms typically begin within hours of the precipitating drug exposure and progress rapidly. With discontinuation of all serotonergic agents and initiation of supportive care, most patients experience symptom resolution within 24 to 72 hours ^[125]C4. In the majority of serotonin syndrome cases, symptoms resolve rapidly after treatment initiation and discontinuation of the offending agents ^[125]C4. Severe cases, particularly those involving massive overdoses or sustained-release formulations, may require prolonged intensive care. One patient with citalopram overdose and intermediate CYP2C19 metabolism had protracted symptoms requiring critical care for 14 days ^[125]C4. In a case series of patients with peripheral neuropathy and serotonin syndrome, all responded to cyproheptadine within 5 days to 2 weeks ^[128]C4. Infants can recover more quickly; a 12-month-old with ondansetron overdose improved over 24 hours and was discharged without sequelae ^[87]C4.

Factors Influencing Outcome

• Severity of serotonin excess: Mild cases (e.g., tremor, hyperreflexia) resolve rapidly; severe cases with hyperthermia >41°C, rigidity, and autonomic instability carry higher morbidity.
• Drug half-life: Short-acting agents (e.g., linezolid , dextromethorphan) produce shorter symptom duration; long-acting or extended-release formulations (e.g., venlafaxine XR) can prolong toxicity.
• Timeliness of treatment: Early administration of benzodiazepines and, when indicated, serotonin antagonists (e.g., cyproheptadine) improves outcomes.
• Comorbidities: Polyneuropathy may mask clonus and hyperreflexia, delaying diagnosis and treatment ^[128]C4.
• Age: Infants and young children may have more rapid recovery but are vulnerable to seizures and obtundation ^[87]C4.

Mortality

Death from serotonin syndrome is rare when recognized early and managed appropriately. However, mortality can occur in severe cases, especially with massive overdoses or delayed treatment. In a case series of four patients with large venlafaxine overdoses (3150-13,500 mg), three died from refractory hypoxemia, malignant arrhythmias, or cardiogenic shock ^[80]C4. The combination of fentanyl and linezolid in mechanically ventilated patients was associated with increased in-hospital mortality (HR 1.56; 95% CI 1.00-2.43; P = 0.049) ^[84]B2b, highlighting the risk of drug interactions that precipitate serotonin syndrome. No deaths were reported in the CENTURION trial of lasmiditan, where two patients developed serotonin syndrome but recovered ^[103]A1b.

Long-Term Outcomes

Full recovery without permanent sequelae is the rule. No specific long-term neurologic or psychiatric deficits have been consistently attributed to serotonin syndrome itself. Recurrence is possible if serotonergic agents are restarted without dose adjustment or without avoiding interacting drugs. Patients should be counseled on prevention strategies before discharge.

Pearl: The key to a favorable prognosis is early recognition and aggressive supportive care, most patients recover fully within days, but a missed diagnosis or delayed treatment can turn a reversible condition into a fatal one.

Prognosis is excellent with early recognition, but the standard diagnostic and therapeutic pathway requires modification in four vulnerable populations: children, pregnant patients, the elderly, and the immunocompromised.

Pediatrics

• Presentation may include seizure, rhabdomyolysis , and hyperthermia more prominently than in adults ^[134]D5.
• The differential diagnosis must include infection, malignant hyperthermia , and anticonvulsant toxicity.
• Management follows weight-based protocols for benzodiazepines and aggressive fluid resuscitation for rhabdomyolysis ^[134]D5.
• Cyproheptadine is used with weight-based dosing when severe symptoms persist.

Pregnancy

• Serotonin syndrome can be precipitated by antiemetics (ondansetron, prochlorperazine) and triptans used for hyperemesis gravidarum ^[133]C4.
• Perioperative recognition is challenging during cesarean delivery; symptoms may mimic preeclampsia or eclampsia ^[57]C4.
• Neonatal toxicity: in utero exposure to combined serotonergic agents (e.g., venlafaxine + bupropion + quetiapine) can cause encephalopathy and abnormal movements at birth ^[135]D5.
• Management: supportive care and benzodiazepines are first-line ^[133]C4; cyproheptadine may be considered if severe, though safety data in pregnancy are limited.
• Delivery planning: if serotonin syndrome occurs near term, consider fetal monitoring; neonatal providers should be alerted to the maternal serotonergic medication list ^[135]D5.

Elderly

• Polypharmacy is a major risk factor: 2.4% of older patients on ≥5 medications have high or moderate risk for serotonergic interactions ^[34]C4.
• Drugs commonly involved in multidrug interactions that amplify serotonin syndrome risk include bupropion, tramadol, trazodone, cyclobenzaprine, fluoxetine , ondansetron, and quetiapine ^[36]C4.
• Antidepressant switching is often non-guideline-concordant (48% of switches), increasing serotonin syndrome risk ^[136]B2b.
• Presentation may be atypical: delirium, falls, or cognitive decline rather than the classic triad ^[137]B3b.
• Overlap with Parkinson's disease symptoms (tremor, rigidity) can delay diagnosis ^[50]C4.
• Management: reduce serotonergic burden; avoid high-risk combinations; use lower initial doses of benzodiazepines; monitor for QT prolongation (age is associated with fatality from drug-induced QT prolongation, OR 1.03 per year, 95% CI 1.01-1.07) ^[54]D5.

Immunocompromised

• Linezolid , a monoamine oxidase inhibitor antibiotic, combined with serotonergic drugs (SSRIs, opioids) significantly increases serotonin syndrome risk.
• In mechanically ventilated patients, concurrent linezolid and fentanyl was associated with increased in-hospital mortality (HR 1.56, 95% CI 1.00-2.43) ^[84]B2b.
• COVID-19 patients may present with myoclonus and other abnormal movements; serotonin syndrome should be considered in the differential ^[119]C4.
• Management: avoid linezolid in patients on SSRIs/SNRIs if alternatives exist; if unavoidable, monitor closely for serotonin syndrome symptoms and consider dose reduction of serotonergic agents.

Pearl: In elderly patients with Parkinson's disease, serotonin syndrome may be mistaken for worsening parkinsonism ; a detailed medication history and the presence of clonus or hyperreflexia help distinguish the two ^[50]C4.

Having considered the particular challenges of serotonin syndrome in pregnancy and special populations, the emergency clinician's role extends to prevention across the visit continuum. The ED encounter is a public-health touchpoint where primary, secondary, and tertiary prevention actions can be completed in the same visit, each anchored to a guideline class.

Primary Prevention: Avoiding Harmful Drug Combinations

The most common cause of serotonin syndrome is polypharmacy, the unintended combination of serotonergic agents. In a population-based cohort of older adults, 18.1% of patients treated with an irreversible MAOI were concomitantly exposed to at least one other serotonergic drug ^[1]B2b. Although no ED visits or acute care admissions for serotonin syndrome were identified in that study, the potential for harm is well documented ^[1]B2b. Emergency clinicians should review every patient's medication list for serotonergic duplications, particularly when initiating a new agent or when a patient presents with unexplained symptoms. Fentanyl , frequently used for procedural sedation, may precipitate serotonin syndrome in patients chronically taking SSRIs or other serotonergic drugs ^[5]C4. In patients on serotonergic antidepressants, consider alternative analgesics or sedatives when feasible.

Secondary Prevention: Preventing Recurrence After an Episode

After a confirmed or suspected episode of serotonin syndrome, the key is to identify and discontinue the precipitating drug combination. A systematic review of antidepressant-related adverse events found that evidence is unclear about the comparative risks of serotonin syndrome among second-generation antidepressants, but the risk exists ^[140]D5. In a tertiary care cancer center, 40% of patients on antidepressants had a potential major drug interaction that could lead to serotonin syndrome symptoms, and such interactions were associated with increased hospital and ED visits (OR 2.28, 95% CI 1.33-3.92) ^[4]B2b. Before discharge, ensure that the offending agent(s) are stopped and that the patient's primary care provider or psychiatrist is notified to avoid re-challenge. Document the episode clearly in the patient's record to guide future prescribing.

Patient Education and Discharge Instructions

Educate patients and caregivers about the signs of serotonin excess: agitation, confusion, rapid heart rate, muscle twitching, and diarrhea. Instruct them to seek immediate medical attention if these symptoms recur, especially after a medication change. Provide written discharge instructions that list the specific drugs involved and a recommendation to avoid serotonergic combinations unless directed by a specialist. Although no vaccine or screening test exists for serotonin syndrome, the ED visit offers an opportunity to perform a medication reconciliation, a simple but powerful intervention that can prevent future admissions ^[4]B2b.

Pearl: The single most preventable cause of serotonin syndrome in the ED is co-prescribing of serotonergic agents without reconciliation, a thorough medication review at every visit can reduce the risk of both initial and recurrent episodes.